Phil Thomas

When searching through Pharma Footpath for a product you may not have sourced very often, or even entirely new, you can sometimes find that a suprising price in a market you don't have strong relationships. What then?

Using the EU WDA License tool in Pharma Footpath gives you chance to review who has licenses in different markets, and the conditions on their licenses!

Let's imagine you need a cold chain product, and you've seen the list price information in Greece suggests this might be a good market to speak to suppliers. It's not a market you've strong relationships with, so you're looking for all options. By applying a couple of simple filters, you can select all WDA license holders in Greece who have both 'cold chain' as a license condition, as well as 'export'.

In which case, you only have 48 WDA license holders that meet these conditions. Some of these may be irrelevant, logistics providers for example, and now you're left with a shortlist of companies to evaluate and see whether there are potential new partners.

This may take a little bit of time to evaluate, but this time invested expands your network and can reveal some opportunities that competitors haven't taken the time to explore!

If you'd like to discuss more about the information in WDA licenses, or how we can use data to enhance your business, please reply to this email and let's discuss!

Phil

Some markets are more difficult to gather detailed information from, and the Italian market falls in that category. That means that when we do run analytics on the market, it's important to share!

- 1,482 parallel trade licenses have been granted to bring stock into Italy, though 248 are no longer commercialised.

- 17 different companies hold these licenses. GMM Farma being the biggest with 269 licenses approved, including 24 licenses granted in 2024.

- Bayer's oral contraceptive Yasmin is the most contested parallel import product, with 12 different companies holding PI licenses for this.

- Of the 223 different products imported (that is, excluding different strengths and pack size variations), 67 are held by a single company without competition.

- In line with the wider PI industry, the number of licenses granted per quarter has increased steadily over the last 10 years. From an average of 9.75 licenses per quarter in 2013, to 48 per quarter in 2023.

The rise in competition for parallel import products, and the growth in the industry more broadly, has resulted in companies looking for a new 'edge' that allows them to compete more effectively. Pharma Footpath has been working with parallel import companies to identify new opportunities before others, and track competition more effectively.

If you're interested in seeing what data analytics we can provide for your business, you can reply to this message and let me know what you're keen to learn more about!

Phil

As Pharma Footpath develops its databases, we're able to quickly drill down into the commercial opportunities. Where I think this is most interesting currently is in looking at renegotiated prices in different markets, and taking advantage of these before others do.

Examples of this include:

- 50% reduction in price for Australian Xolair PFS, bringing this below EU market. Valuable for the 54 clinical trials globally, and for the wider number of trading opportunities that come from these English language packs

- The centrally authorised product Pradaxa has had over 300 parallel trade licenses granted, and is listed in 65 clinical trials globally. A recent price reduction of over 20% in Hungary makes this an import area to review

It's clear from the data that when price changes occur, they don't happen in a synchronized fashion. That creates opportunities for finding the markets that have the earliest price movement, but also acts as a warning to companies about committing to purchasing product that may be about to undergo significant market changes (Revlimid is a prime example in Europe!)

If you'd like to talk more about these points, please get in touch! I'm always keen to talk more about the insights we're finding, and what we can build from it to make your business win more.

Phil

The Netherlands has been the biggest trading market in Europe that PharmaFootpath had yet to include. I'm pleased to share we've now included the centralised product pricing, national product registrations will follow in the near future.

Adding a new country to our data takes some time as we have a number of steps to go through to ensure we have data integrity:

• Agree data source for country (for example, we have an agreement with government in Germany to transfer data every 2 weeks)
• Review data, isolating the data required for our database and identify any gaps
• Translate the various APIs, presentations, routes, weights, and other data
• Restructure data to match our schema
• Run quality checks to ensure compliance with our standards, investigate each failure and resolve
• Import data

This process is time consuming, and filled with complex edge cases, and often the origin data itself has mistakes included that we need to investigate. However, when we finish this, the end result is a well structured database that provides us with a valuable dataset that we can quickly interrogate and find new information.

I'm delighted we're continuing to add to this, and getting closer to our goals!

Phil

(If you've any questions about this, please feel free to message me to learn more!)